ARTV missed EPS expectations by 7.78%
Mar 26, 2025, 10:32 PM
0.00%
What does ARTV do
Artiva Biotherapeutics, based in San Diego, focuses on NK cell-based therapies for autoimmune diseases and cancers, with its lead candidate AlloNK in Phase I/Ib trials. The company went public on July 19, 2024.
Artiva Biotherapeutics (ARTV) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Artiva Biotherapeutics's actual EPS was -$0.83, missing the estimate of -$0.77 per share, resulting in a -7.78% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
